2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

[1]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[2]  D. De Bacquer,et al.  Cardiovascular risk estimation in older persons: SCORE O.P. , 2016, European journal of preventive cardiology.

[3]  Biao Xu,et al.  Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. , 2016, Annals of internal medicine.

[4]  A. Rodday,et al.  Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) , 2016, Circulation.

[5]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[6]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[7]  H. Soran,et al.  Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. , 2015, European heart journal.

[8]  M. James,et al.  Guidelines for Classification of Acute Kidney Diseases and Disorders , 2015, Nephron.

[9]  G. Helft,et al.  Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. , 2015, Archives of cardiovascular diseases.

[10]  Peter Scarborough,et al.  Cardiovascular disease in Europe--epidemiological update 2015. , 2015, European heart journal.

[11]  D. Francis,et al.  What proportion of symptomatic side-effects in patients taking statins are genuinely caused by the drug? A response to letters , 2015, European journal of preventive cardiology.

[12]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[13]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[14]  K. Sakamoto,et al.  Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. , 2015, Journal of the American College of Cardiology.

[15]  V. Aboyans,et al.  The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. , 2015, Atherosclerosis.

[16]  C. Ip,et al.  Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. , 2015, International journal of cardiology.

[17]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[18]  E. Falk,et al.  The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study , 2015, European heart journal.

[19]  V. Medici,et al.  A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. , 2015, The American journal of clinical nutrition.

[20]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[21]  M. Hagger,et al.  Theory of planned behavior and adherence in chronic illness: a meta-analysis , 2015, Journal of Behavioral Medicine.

[22]  Gretchen A. Stevens,et al.  A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. , 2015, The lancet. Diabetes & endocrinology.

[23]  A. Massicotte,et al.  Statins and their effect on cognition , 2015, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[24]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[25]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[26]  P. Wilson,et al.  Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. , 2015, Journal of the American College of Cardiology.

[27]  Andrew E Moran,et al.  Demographic and epidemiologic drivers of global cardiovascular mortality. , 2015, The New England journal of medicine.

[28]  Marja-Riitta Taskinen,et al.  New insights into the pathophysiology of dyslipidemia in type 2 diabetes. , 2015, Atherosclerosis.

[29]  Deepak L. Bhatt,et al.  Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study , 2015, European journal of preventive cardiology.

[30]  Yanyun Zhao,et al.  Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. , 2015, Journal of ethnopharmacology.

[31]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[32]  S. Capewell,et al.  Comparing Different Policy Scenarios to Reduce the Consumption of Ultra-Processed Foods in UK: Impact on Cardiovascular Disease Mortality Using a Modelling Approach , 2015, PloS one.

[33]  D. Margolis,et al.  Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[34]  Alex P. Reiner,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[35]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[36]  A. Ross,et al.  Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. , 2015, The American journal of clinical nutrition.

[37]  Sonia Shah,et al.  Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. , 2015, Clinical chemistry.

[38]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[39]  R. Rosenheck,et al.  Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. , 2014, JAMA psychiatry.

[40]  V. Fuster,et al.  A polypill strategy to improve adherence: results from the FOCUS project. , 2014, Journal of the American College of Cardiology.

[41]  P. Thompson,et al.  Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. , 2014, Journal of clinical lipidology.

[42]  John Spertus,et al.  Inactivating mutations in NPC1L1 and protection from coronary heart disease. , 2014, The New England journal of medicine.

[43]  Deepak L. Bhatt,et al.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. , 2014, European heart journal.

[44]  J. Tomassini,et al.  Combination therapy in dyslipidemia: where are we now? , 2014, Atherosclerosis.

[45]  A Kamran,et al.  Determinants of Patient's Adherence to Hypertension Medications: Application of Health Belief Model Among Rural Patients , 2014, Annals of medical and health sciences research.

[46]  M. Leboyer,et al.  Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. , 2014, The Journal of clinical psychiatry.

[47]  J. Chardigny,et al.  Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials , 2014, British Journal of Nutrition.

[48]  Ž. Reiner.  Resistance and intolerance to statins. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[49]  M. Farkouh,et al.  Statins and contrast-induced acute kidney injury with coronary angiography. , 2014, The American journal of medicine.

[50]  G. Vorobiof,et al.  Insights Into Aortic Sclerosis and Its Relationship With Coronary Artery Disease , 2014, Journal of the American Heart Association.

[51]  E. Livingston,et al.  Long-term follow-up after bariatric surgery: a systematic review. , 2014, JAMA.

[52]  F. Kronenberg,et al.  Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. , 2014, Journal of the American College of Cardiology.

[53]  S. Pocock,et al.  to improve adherence : results from FOCUS ( Fixed-dose Combination Drug for Secondary Cardiovascular Prevention ) Project , 2014 .

[54]  A. Keech,et al.  Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study , 2014, Diabetologia.

[55]  J. Borén,et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[56]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[57]  P. Ridker,et al.  Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.

[58]  J. Borén,et al.  Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management , 2022 .

[59]  Darrel P Francis,et al.  Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients , 2014, BMJ : British Medical Journal.

[60]  A. Wierzbicki,et al.  Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance , 2014, BMJ : British Medical Journal.

[61]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[62]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[63]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[64]  R. Elkeles,et al.  Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[65]  Kees Hovingh,et al.  Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. , 2014, Atherosclerosis.

[66]  J. Critchley,et al.  An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[67]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[68]  Janusz Wnek,et al.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[69]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[70]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[71]  G. Watts,et al.  Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.

[72]  J. Wise.  Open letter raises concerns about NICE guidance on statins , 2014, BMJ : British Medical Journal.

[73]  Long Jiang,et al.  A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia , 2014, PloS one.

[74]  Ling He,et al.  Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. , 2014, Diabetes research and clinical practice.

[75]  S. Pocock,et al.  Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2014, JACC. Heart failure.

[76]  T. Jørgensen,et al.  Seasonality of cardiovascular risk factors: an analysis including over 230 000 participants in 15 countries , 2014, Heart.

[77]  R. Kelishadi,et al.  Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. , 2014, Nutrition.

[78]  J. Dalen,et al.  Diets to prevent coronary heart disease 1957-2013: what have we learned? , 2014, The American journal of medicine.

[79]  Ž. Reiner.  Primary Prevention of Cardiovascular Disease with Statins in the Elderly , 2014, Current Atherosclerosis Reports.

[80]  Genevieve A Cowie,et al.  Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. , 2014, The Cochrane database of systematic reviews.

[81]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[82]  P. Barter,et al.  Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). , 2014, The American journal of cardiology.

[83]  Stephen S. Lim,et al.  Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys , 2014, BMJ : British Medical Journal.

[84]  Jbs Board.  Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[85]  Simon G Thompson,et al.  Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. , 2014, Annals of internal medicine.

[86]  J. Borén,et al.  Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. , 2014, Atherosclerosis.

[87]  M. Huffman,et al.  Huffman and colleagues’ response to Abramson and colleagues’ article on statins in low risk people , 2014, BMJ : British Medical Journal.

[88]  H. Bang,et al.  Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. , 2014, Journal of the American College of Cardiology.

[89]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[90]  M. Olandoski,et al.  Validation of the Friedewald Formula in Patients with Metabolic Syndrome , 2014, Cholesterol.

[91]  M. Tonelli,et al.  Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. , 2014, Annals of internal medicine.

[92]  J. Whitfield.  Genetic insights into cardiometabolic risk factors. , 2014, The Clinical biochemist. Reviews.

[93]  D. Benaiges,et al.  Type 1 diabetes, metabolic syndrome and cardiovascular risk. , 2014, Metabolism: clinical and experimental.

[94]  J. Borén,et al.  Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. , 2014, Atherosclerosis.

[95]  Jennifer R. Harris,et al.  The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies , 2014, BMC Endocrine Disorders.

[96]  Ž. Reiner.  Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia , 2014, Circulation research.

[97]  A. Husseini,et al.  A Cost Effectiveness Analysis of Salt Reduction Policies to Reduce Coronary Heart Disease in Four Eastern Mediterranean Countries , 2014, PloS one.

[98]  G. Norata,et al.  Targeting PCSK9 for hypercholesterolemia. , 2014, Annual review of pharmacology and toxicology.

[99]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[100]  I. Ford,et al.  Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study , 2013, European heart journal.

[101]  R. Haynes,et al.  Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.

[102]  J. Shaw,et al.  Diabetes: a 21st century challenge. , 2014, The lancet. Diabetes & endocrinology.

[103]  Christina Jackson,et al.  Applying COM-B to medication adherence , 2014 .

[104]  B. Nordestgaard,et al.  Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. , 2014, Journal of clinical lipidology.

[105]  Abstr Act,et al.  Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease , 2014 .

[106]  I. Thompson,et al.  Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. , 2014, Journal of the National Cancer Institute.

[107]  Sandra C. Fuchs,et al.  HIV Infection and Cardiovascular Disease , 2013, The Scientific World Journal.

[108]  R. Malekzadeh,et al.  Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. , 2013, The Cochrane database of systematic reviews.

[109]  K. Bennett,et al.  Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008 , 2013, BMC Public Health.

[110]  C. Andrade.  Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins , 2013, Bipolar disorders.

[111]  D. Droste,et al.  A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial , 2013, Nutrition Journal.

[112]  N. Jewell,et al.  Should people at low risk of cardiovascular disease take a statin? , 2013, BMJ.

[113]  A. Lichtenstein,et al.  Dietary Cholesterol and Plasma Lipoprotein Profiles: Randomized Controlled Trials , 2013, Current Nutrition Reports.

[114]  Peter Scarborough,et al.  Cardiovascular disease in Europe: epidemiological update. , 2014, European heart journal.

[115]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[116]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[117]  R. Christensen,et al.  Whole grain and body weight changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. , 2013, The American journal of clinical nutrition.

[118]  A. Demchuk,et al.  Reduction in Early Stroke Risk in Carotid Stenosis With Transient Ischemic Attack Associated With Statin Treatment , 2013, Stroke.

[119]  D. Prabhakaran,et al.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.

[120]  M. Banach,et al.  Acute coronary syndromes in patients with chronic kidney disease. , 2013, Current vascular pharmacology.

[121]  Michael R. Jones,et al.  Role of Colesevelam in Combination Lipid-Lowering Therapy , 2013, American Journal of Cardiovascular Drugs.

[122]  A. Gotto,et al.  Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. , 2013, Journal of the American College of Cardiology.

[123]  Chi Pang Wen,et al.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[124]  O. Wiklund,et al.  Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy , 2013, Current Cardiology Reports.

[125]  Huseyin Naci,et al.  Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials , 2013, Circulation. Cardiovascular quality and outcomes.

[126]  S. Hazen,et al.  Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[127]  Z. Kabir,et al.  Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland , 2013, BMJ Open.

[128]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[129]  M. Pencina,et al.  Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. , 2013, Pharmacological research.

[130]  R. Hegele,et al.  Apolipoprotein C-III: going back to the future for a lipid drug target. , 2013, Circulation research.

[131]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[132]  T. Brennan,et al.  Gender and racial disparities in adherence to statin therapy: a meta-analysis. , 2013, American heart journal.

[133]  Dolores Corella,et al.  Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[134]  D. Mozaffarian,et al.  Plasma Phospholipid Long-Chain-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults A Cohort Study , 2013 .

[135]  K. Reynolds,et al.  Primary nonadherence to statin therapy: patients' perceptions. , 2013, The American journal of managed care.

[136]  D. Owens,et al.  Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. , 2013, Journal of the American College of Cardiology.

[137]  I. Olkin,et al.  Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review , 2013, PloS one.

[138]  C. Abraham,et al.  The Behavior Change Technique Taxonomy (v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for the Reporting of Behavior Change Interventions , 2013, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[139]  B. Nordestgaard,et al.  Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. , 2013, Journal of the American College of Cardiology.

[140]  M. Banach,et al.  The risk of atherosclerosis in patients with chronic kidney disease , 2013, International Urology and Nephrology.

[141]  Erling Falk,et al.  Update on acute coronary syndromes: the pathologists' view. , 2013, European heart journal.

[142]  J. Guyton,et al.  Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy , 2013, The Annals of pharmacotherapy.

[143]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[144]  K. Torén,et al.  Stroke and coronary heart disease: predictive power of standard risk factors into old age—long-term cumulative risk study among men in Gothenburg, Sweden , 2013, European heart journal.

[145]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[146]  P. Thompson,et al.  Effect of Statins on Skeletal Muscle Function , 2012, Circulation.

[147]  J. Kastelein,et al.  Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. , 2012, Journal of the American College of Cardiology.

[148]  H. Takagi,et al.  Reply to 'Comment on effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies'. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[149]  Karine Tremblay,et al.  Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial , 2012, Gene Therapy.

[150]  D. Simons-Morton,et al.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatrics.

[151]  MartaPereira,et al.  Explaining the Decline in Coronary Heart Disease Mortality in Portugal Between 1995 and 2008 , 2013 .

[152]  L. Hooper,et al.  Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[153]  Yangfeng Wu,et al.  Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials. , 2013, Journal of atherosclerosis and thrombosis.

[154]  André Tchernof,et al.  Pathophysiology of human visceral obesity: an update. , 2013, Physiological reviews.

[155]  N. Sattar,et al.  Revisiting the links between glycaemia, diabetes and cardiovascular disease , 2013, Diabetologia.

[156]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[157]  Jennifer G. Robinson,et al.  Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. , 2012, The American journal of cardiology.

[158]  A. Keech,et al.  Effects of fibrates in kidney disease: a systematic review and meta-analysis. , 2012, Journal of the American College of Cardiology.

[159]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[160]  W. S. Yancy,et al.  Systematic review and meta‐analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[161]  V. Perkovic,et al.  Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis , 2012, Circulation. Cardiovascular quality and outcomes.

[162]  M. Buxton,et al.  Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach , 2012, BMJ Open.

[163]  C. Ballantyne,et al.  Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). , 2012, The American journal of cardiology.

[164]  E. Ntzani,et al.  Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. , 2012, JAMA.

[165]  J. Després,et al.  Body Fat Distribution and Risk of Cardiovascular Disease: An Update , 2012, Circulation.

[166]  Jianyun Wu,et al.  Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta‐analysis , 2012, HIV medicine.

[167]  D. Wald,et al.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. , 2012, The American journal of medicine.

[168]  F. Sacks,et al.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[169]  D. Goff,et al.  Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. , 2012, JAMA.

[170]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[171]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[172]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[173]  S. Linnebur,et al.  FDA drug safety communications: a narrative review and clinical considerations for older adults. , 2012, The American journal of geriatric pharmacotherapy.

[174]  W. Kostis,et al.  Statin Therapy and the Risk of Intracerebral Hemorrhage: A Meta-Analysis of 31 Randomized Controlled Trials , 2012, Stroke.

[175]  T. Vos,et al.  Which Interventions Offer Best Value for Money in Primary Prevention of Cardiovascular Disease? , 2012, PloS one.

[176]  A. Keech,et al.  Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study , 2012, Clinical chemistry and laboratory medicine.

[177]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[178]  W. Kraus,et al.  Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I. , 2012, American heart journal.

[179]  B. Lindkvist,et al.  A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[180]  J. Gallacher,et al.  Lipid-related markers and cardiovascular disease prediction. , 2012, JAMA.

[181]  O. Norheim,et al.  Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis , 2012, BMC Cardiovascular Disorders.

[182]  P. Ridker,et al.  Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2012, Circulation. Cardiovascular genetics.

[183]  A. Zwinderman,et al.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. , 2012, JAMA.

[184]  A. Hofman,et al.  Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification , 2012, Annals of Internal Medicine.

[185]  A. Rosengren.  Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? , 2012, European heart journal.

[186]  R. West,et al.  Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010. , 2012, European heart journal.

[187]  Bonnie Spring,et al.  Healthy Lifestyle Through Young Adulthood and the Presence of Low Cardiovascular Disease Risk Profile in Middle Age: The Coronary Artery Risk Development in (Young) Adults (CARDIA) Study , 2012, Circulation.

[188]  Raimund Erbel,et al.  [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[189]  John Simes,et al.  Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.

[190]  M. Burtscher.  Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.

[191]  T. A. Jacobson,et al.  Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. , 2012, Journal of clinical lipidology.

[192]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[193]  H. Takagi,et al.  Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[194]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[195]  R. Collins,et al.  Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial , 2011 .

[196]  M. Postma,et al.  Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: A scenario analysis for the Netherlands , 2011 .

[197]  P. Engelfriet,et al.  The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population , 2011, BMJ Open.

[198]  T. A. Jacobson,et al.  Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis , 2011, Current atherosclerosis reports.

[199]  R. Hart,et al.  Statins for women with polycystic ovary syndrome not actively trying to conceive. , 2011, The Cochrane database of systematic reviews.

[200]  D. Mozaffarian,et al.  United Nations’ dietary policies to prevent cardiovascular disease , 2011, BMJ : British Medical Journal.

[201]  Inger Ekman,et al.  Medication adherence: a call for action. , 2011, American heart journal.

[202]  T. Laursen.  Life expectancy among persons with schizophrenia or bipolar affective disorder , 2011, Schizophrenia Research.

[203]  C. Ballantyne,et al.  Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). , 2011, The American journal of cardiology.

[204]  G. Baio,et al.  Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. , 2011, Atherosclerosis.

[205]  J. Saver,et al.  Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. , 2011, Atherosclerosis.

[206]  V. Salomaa,et al.  An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[207]  E. Colman,et al.  Weighing the benefits of high-dose simvastatin against the risk of myopathy. , 2011, The New England journal of medicine.

[208]  T. Couffinhal,et al.  Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study , 2011, BMC cardiovascular disorders.

[209]  K. Musa-Veloso,et al.  A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[210]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[211]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[212]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[213]  B. Nordestgaard,et al.  Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. , 2011, Current vascular pharmacology.

[214]  C. Furberg,et al.  A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk , 2011, Circulation. Cardiovascular quality and outcomes.

[215]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[216]  S. Michie,et al.  The behaviour change wheel: A new method for characterising and designing behaviour change interventions , 2011, Implementation science : IS.

[217]  Paul M Ridker,et al.  Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). , 2011, Journal of the American College of Cardiology.

[218]  C. Cannon,et al.  Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies , 2011, Circulation.

[219]  Eliseo Guallar,et al.  Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study , 2011, European heart journal.

[220]  Marie T. Brown,et al.  Medication adherence: WHO cares? , 2011, Mayo Clinic proceedings.

[221]  L. Wilhelmsen,et al.  Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden , 2011, Journal of internal medicine.

[222]  D. Panagiotakos,et al.  The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. , 2011, Journal of the American College of Cardiology.

[223]  M. Abrahamowicz,et al.  Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study , 2011, Annals of the rheumatic diseases.

[224]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[225]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[226]  Cindy Brach,et al.  Developing and testing the health literacy universal precautions toolkit. , 2011, Nursing outlook.

[227]  P. Austin,et al.  Statins and renovascular disease in the elderly: a population-based cohort study. , 2011, European heart journal.

[228]  B. Nordestgaard,et al.  Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. , 2011, Clinical chemistry.

[229]  W. Ghali,et al.  Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies , 2011, BMJ : British Medical Journal.

[230]  P. Touboul,et al.  Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis , 2011, Journal of cardiovascular pharmacology.

[231]  A. Thompson,et al.  Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[232]  G. Guyatt,et al.  Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.

[233]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[234]  J. Ballenger.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) , 2011 .

[235]  G. Moneta.  Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants , 2011 .

[236]  A. Alwan.  Global status report on noncommunicable diseases 2010. , 2011 .

[237]  Lun Li,et al.  Statins for primary prevention of venous thromboembolism. , 2011, The Cochrane database of systematic reviews.

[238]  B. Nordestgaard,et al.  Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. , 2011, Current vascular pharmacology.

[239]  F. Paccaud,et al.  Statins for Cardiovascular Prevention According to Different Strategies , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[240]  N. Ames,et al.  β-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials , 2010, European Journal of Clinical Nutrition.

[241]  J. Pais,et al.  The Epidemiology of Excess Mortality in People with Mental Illness , 2010, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[242]  R. Frikke-Schmidt,et al.  Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. , 2010, The Journal of clinical endocrinology and metabolism.

[243]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[244]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[245]  V. Gudnason,et al.  Analysing the Large Decline in Coronary Heart Disease Mortality in the Icelandic Population Aged 25-74 between the Years 1981 and 2006 , 2010, PloS one.

[246]  A. Cass.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[247]  A. Mitchell,et al.  Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis , 2010, Journal of psychopharmacology.

[248]  David J. Becker,et al.  Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! , 2010, Archives of internal medicine.

[249]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[250]  Dirk De Bacquer,et al.  EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[251]  T. Wolever,et al.  Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. , 2010, The American journal of clinical nutrition.

[252]  Lawrence Joseph,et al.  The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.

[253]  M. Woodward,et al.  Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis , 2010, The Annals of pharmacotherapy.

[254]  Ralph D'Agostino,et al.  Risk Prediction in Cardiovascular Medicine Cardiovascular Risk-Estimation Systems in Primary Prevention Do They Differ ? Do They Make a Difference ? Can We See the Future ? , 2010 .

[255]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[256]  P. Passmore,et al.  Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.

[257]  J Wouter Jukema,et al.  Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.

[258]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[259]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[260]  R. Aubert,et al.  Is there a relationship between early statin compliance and a reduction in healthcare utilization? , 2010, The American journal of managed care.

[261]  A. Keech,et al.  Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes , 2010, Diabetologia.

[262]  Pierre Amarenco,et al.  Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. , 2010, Atherosclerosis.

[263]  P. Barter,et al.  Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database , 2010, Journal of Lipid Research.

[264]  P. Giral,et al.  Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. , 2010, Pharmacology & therapeutics.

[265]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[266]  R. Arora,et al.  Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. , 2010, International journal of cardiology.

[267]  B. Popescu,et al.  Effect of Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors on the Long-Term Progression of Rheumatic Mitral Valve Disease , 2010, Circulation.

[268]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[269]  R. Cote,et al.  Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs , 2010, Medical care.

[270]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[271]  J. Liao,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[272]  Robert J. Glynn,et al.  Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.

[273]  Shu-Hua Tai,et al.  A systematic review and meta‐analysis on the therapeutic equivalence of statins , 2010, Journal of clinical pharmacy and therapeutics.

[274]  O. Melander,et al.  Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. , 2010, Journal of the American College of Cardiology.

[275]  Y. Jang,et al.  Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. , 2010, JACC. Cardiovascular interventions.

[276]  D. Mozaffarian,et al.  Effects on Coronary Heart Disease of Increasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010, PLoS medicine.

[277]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[278]  T. Frieden.  A framework for public health action: the health impact pyramid. , 2010, American journal of public health.

[279]  G. Mancia,et al.  Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. , 2010, Clinical therapeutics.

[280]  Simon Capewell,et al.  Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. , 2010, Bulletin of the World Health Organization.

[281]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[282]  D. Symmons,et al.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[283]  B. Gersh.  Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002 , 2010 .

[284]  P. Plans-Rubió.  The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices , 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[285]  P. Hardt,et al.  Severe hypertriglyceridemia and pancreatitis: presentation and management , 2009, Current opinion in lipidology.

[286]  B. G. Brown,et al.  Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed For , 2009, The American journal of cardiology.

[287]  A. Colombo,et al.  Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. , 2009, Journal of the American College of Cardiology.

[288]  G. Kelley,et al.  Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals. , 2009, Preventive Medicine.

[289]  Jeroen J. Bax,et al.  Fluvastatin and perioperative events in patients undergoing vascular surgery. , 2009, The New England journal of medicine.

[290]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[291]  D. Gladman,et al.  Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus , 2009, Journal of Rheumatology.

[292]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[293]  K. Olson,et al.  Statin adherence and mortality in patients enrolled in a secondary prevention program. , 2009, The American journal of managed care.

[294]  P. Whincup,et al.  Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[295]  P. Whincup,et al.  HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. , 2009, Atherosclerosis.

[296]  I. Graham,et al.  Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. , 2009, Journal of the American College of Cardiology.

[297]  G. Costabile,et al.  Effects of a Plant-Based High-Carbohydrate/High-Fiber Diet Versus High–Monounsaturated Fat/Low-Carbohydrate Diet on Postprandial Lipids in Type 2 Diabetic Patients , 2009, Diabetes Care.

[298]  David J Kupfer,et al.  Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. , 2009, Bipolar disorders.

[299]  H. Möller,et al.  Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) , 2009, European Psychiatry.

[300]  Antti Tanskanen,et al.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) , 2009, The Lancet.

[301]  V. Pasceri,et al.  Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. , 2009, Journal of the American College of Cardiology.

[302]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[303]  J. Benner,et al.  The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[304]  Ian Graham,et al.  How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[305]  A. Keech,et al.  Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate , 2009, Arteriosclerosis, Thrombosis and Vascular Biology.

[306]  D. Mozaffarian,et al.  Health effects of trans-fatty acids: experimental and observational evidence , 2009, European Journal of Clinical Nutrition.

[307]  P. Amarenco,et al.  Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.

[308]  Simon Capewell,et al.  Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. , 2009, European heart journal.

[309]  J. Ordovás.  Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. , 2009, The American journal of clinical nutrition.

[310]  Wei Zhang,et al.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. , 2009, The Journal of clinical investigation.

[311]  Sonia S Anand,et al.  A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. , 2009, Archives of internal medicine.

[312]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[313]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[314]  J. Fildes,et al.  The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin , 2009, Transplantation.

[315]  James W. Anderson,et al.  Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. , 2009, Atherosclerosis.

[316]  G. Hitman,et al.  Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). , 2009, Clinical chemistry.

[317]  D. Mozaffarian,et al.  Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[318]  J. Kastelein,et al.  Combination statin–fibrate therapy: safety aspects , 2009, Diabetes, obesity & metabolism.

[319]  M. Neyt,et al.  Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium , 2009, Acta cardiologica.

[320]  Jennifer G. Robinson,et al.  Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.

[321]  C. N. Bairey Merz,et al.  Contraceptive hormone use and cardiovascular disease. , 2009, Journal of the American College of Cardiology.

[322]  A. Keech,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[323]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, The Cochrane database of systematic reviews.

[324]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[325]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis , 2014, The Cochrane database of systematic reviews.

[326]  Edward J. Mills,et al.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[327]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[328]  G. Chodick,et al.  Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. , 2008, Clinical therapeutics.

[329]  F. Sacks,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[330]  N. Paynter,et al.  C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men , 2008, Circulation.

[331]  D. Waters,et al.  Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[332]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[333]  Gissi-Hf Investigators.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[334]  M. Petticrew,et al.  Developing and evaluating complex interventions: the new Medical Research Council guidance , 2008, BMJ : British Medical Journal.

[335]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[336]  P. Jones,et al.  Plant sterols/stanols as cholesterol lowering agents: A meta-analysis of randomized controlled trials , 2008, Food & nutrition research.

[337]  J. Liao.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[338]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[339]  A. Sheikh,et al.  Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 , 2008, BMJ : British Medical Journal.

[340]  D. Capuzzi,et al.  Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[341]  O. Faergeman,et al.  Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial , 2008, The Lancet.

[342]  L. Niskanen,et al.  Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men , 2008, Current medical research and opinion.

[343]  V. Kamanna,et al.  Mechanism of action of niacin. , 2008, The American journal of cardiology.

[344]  B. G. Brown,et al.  Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.

[345]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[346]  R. Giacco,et al.  Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. , 2008, Clinical nutrition.

[347]  C. la Vecchia,et al.  Non-pharmacological control of plasma cholesterol levels. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[348]  L. Niskanen,et al.  Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents , 2008, Journal of psychopharmacology.

[349]  O. Faergeman,et al.  Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL) , 2008, Annals of medicine.

[350]  J. Robson,et al.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[351]  G. Fonarow.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : a randomised, double-blind, placebo-controlled trial. Commentary , 2008 .

[352]  S. Allender,et al.  European cardiovascular disease statistics , 2008 .

[353]  R. Karas,et al.  Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. , 2008, The American journal of cardiology.

[354]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[355]  L. Tavazzi,et al.  ect of n-3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI-HF trial ) : a randomised , double-blind , placebo-controlled trial , 1980 .

[356]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[357]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[358]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[359]  J. Price,et al.  Lipid-lowering for peripheral arterial disease of the lower limb. , 2007, The Cochrane database of systematic reviews.

[360]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[361]  M. Pencina,et al.  Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. , 2007, JAMA.

[362]  T. Walley,et al.  Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. , 2007, Health technology assessment.

[363]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[364]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[365]  D. Herrington,et al.  Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease , 2007, Annals of Internal Medicine.

[366]  Hang Lee,et al.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.

[367]  Moyses Szklo,et al.  LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Atherosclerosis.

[368]  S. Grundy,et al.  Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. , 2007, American heart journal.

[369]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[370]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[371]  J. Mckenney,et al.  Safety considerations with fibrate therapy. , 2007, The American journal of cardiology.

[372]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[373]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[374]  Prakash Deedwania,et al.  Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE) , 2007, Circulation.

[375]  Paul Schoenhagen,et al.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.

[376]  D. Waters,et al.  Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study , 2007, Circulation.

[377]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[378]  M. Woodward,et al.  Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) , 2005, Heart.

[379]  W. Howard.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[380]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[381]  J. Golledge,et al.  Atvb in Focus Abdominal Aortic Aneurysms: Pathophysiological Mechanisms and Clinical Implications Abdominal Aortic Aneurysm Pathogenesis and Implications for Management , 2022 .

[382]  J. Lau,et al.  Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. , 2006, Atherosclerosis.

[383]  C. Del Mar,et al.  Exercise for overweight or obesity. , 2006, The Cochrane database of systematic reviews.

[384]  G. Hamilton,et al.  Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? , 2006, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[385]  Milton C Weinstein,et al.  Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis , 2006, The Lancet.

[386]  C. Packard.  Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease , 2006, Current opinion in lipidology.

[387]  P. Hepburn,et al.  Safety evaluation of phytosterol-esters. Part 9: Results of a European post-launch monitoring programme. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[388]  J. Lawson.  Comparative Quantification of Health Risks. Global and Regional Burden of Disease Attributable to Selected Major Risk Factors , 2006 .

[389]  M. Sabatine,et al.  Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. , 2006, Journal of the American College of Cardiology.

[390]  J. Danesh,et al.  Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature‐based meta‐analysis of prospective studies , 2006, Journal of internal medicine.

[391]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[392]  J. Mckenney,et al.  Statin safety: an assessment using an administrative claims database. , 2006, The American journal of cardiology.

[393]  John A. Clark,et al.  Statin safety: an appraisal from the adverse event reporting system. , 2006, American Journal of Cardiology.

[394]  Julian P T Higgins,et al.  Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review , 2006, BMJ : British Medical Journal.

[395]  C. Hollenbeck,et al.  Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. , 2006, The Journal of clinical endocrinology and metabolism.

[396]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[397]  Matthias Briel,et al.  Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[398]  W. März,et al.  Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis , 2006, Clinical Research in Cardiology.

[399]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[400]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[401]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[402]  E. Braunwald,et al.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[403]  Ž. Reiner,et al.  Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. , 2005, The American journal of cardiology.

[404]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[405]  D. Vidt.  Statins and proteinuria , 2005, Current atherosclerosis reports.

[406]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[407]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[408]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[409]  R. Dobson,et al.  Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. , 2005, The Canadian journal of cardiology.

[410]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[411]  Bo Christensen,et al.  Motivational interviewing: a systematic review and meta-analysis. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[412]  Salvatore Panico,et al.  Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. , 2005, International journal of epidemiology.

[413]  T. Evans,et al.  Medication adherence trends with statins , 2005, Advances in therapy.

[414]  N. Chalasani,et al.  Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes , 2005, The American journal of the medical sciences.

[415]  G. Miller,et al.  Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.

[416]  Ž. Reiner,et al.  Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients , 2005, Clinical drug investigation.

[417]  T. Fahey,et al.  Interventions to improve adherence to lipid lowering medication. , 2004, The Cochrane database of systematic reviews.

[418]  B. Caramelli,et al.  Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. , 2005, Journal of vascular surgery.

[419]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[420]  M. Davidson.  Rosuvastatin safety: lessons from the FDA review and post-approval surveillance , 2004, Expert opinion on drug safety.

[421]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[422]  J. Sidaway,et al.  Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. , 2004, Journal of the American Society of Nephrology : JASN.

[423]  J. Davignon.  Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004, Circulation.

[424]  M. Pignone,et al.  Drug treatment of hyperlipidemia in women. , 2004, JAMA.

[425]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[426]  J. Kastelein,et al.  Advanced method for the identification of patients with inherited hypercholesterolemia. , 2004, Seminars in vascular medicine.

[427]  Alan D. Lopez,et al.  Comparative quantification of health risks. Global and regional burden of disease attributable to selected major risk factors. Volume 1. , 2004 .

[428]  M. Conner,et al.  The Theory of Planned Behaviour , 2004 .

[429]  B. Popescu,et al.  Effect of statins on the progression of bioprosthetic aortic valve degeneration. , 2003, The American journal of cardiology.

[430]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[431]  M. Koschinsky,et al.  Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. , 2003, Clinical chemistry.

[432]  P. Greenland,et al.  Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. , 2003, Archives of internal medicine.

[433]  T. Fukui,et al.  The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. , 2003, Preventive medicine.

[434]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[435]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[436]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[437]  S. Cole,et al.  Impact of HIV infection and HAART on serum lipids in men. , 2003, JAMA.

[438]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[439]  A. J. Swerdlow,et al.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes , 2003, Diabetologia.

[440]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[441]  R. Mensink,et al.  Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.

[442]  G. Assmann,et al.  Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. , 2003, Atherosclerosis.

[443]  Leonardo Calza,et al.  Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART , 2003, AIDS.

[444]  A. Louheranta,et al.  Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. , 2003, Atherosclerosis.

[445]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[446]  W. Kraus,et al.  Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.

[447]  Muhammad Mamdani,et al.  Adherence with statin therapy in elderly patients with and without acute coronary syndromes. , 2002, JAMA.

[448]  P. Wilson,et al.  Heart protection study. , 2002, Current cardiology reports.

[449]  P. Thompson,et al.  Magnetic resonance imaging of left atrial thrombus , 2002, Heart.

[450]  J. Faith,et al.  Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. , 2002, Human reproduction.

[451]  M. Weinstein,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[452]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[453]  L. Tavazzi,et al.  Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002 .

[454]  M. Santini,et al.  Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002, Circulation.

[455]  J. Hendriks,et al.  Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[456]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[457]  V. Gudnason,et al.  Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. , 2001, Journal of cardiovascular risk.

[458]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[459]  C. Ballantyne,et al.  Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S , 2001, Circulation.

[460]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[461]  A. Tonkin,et al.  Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial , 2001, Annals of Internal Medicine.

[462]  J. Manson,et al.  Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. , 2001, The American journal of clinical nutrition.

[463]  B. M. Rasmussen,et al.  Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU study , 2001, Diabetologia.

[464]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[465]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[466]  J. Farmer.  Pleiotropic effects of statins , 2000, Current atherosclerosis reports.

[467]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[468]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[469]  E. Rimm,et al.  Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors , 1999, BMJ.

[470]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[471]  M. de Lorgeril,et al.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. , 1999, Circulation.

[472]  J. Illnait,et al.  Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors , 1999, Clinical pharmacology and therapeutics.

[473]  P. Kris-Etherton,et al.  Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. , 1999, The American journal of clinical nutrition.

[474]  Jean-Louis Martin,et al.  Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study , 1999 .

[475]  A. Bandura.  Self-Efficacy: The Exercise of Control , 1997, Journal of Cognitive Psychotherapy.

[476]  B. Rosner,et al.  Cholesterol-lowering effects of dietary fiber: a meta-analysis. , 1999, The American journal of clinical nutrition.

[477]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[478]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[479]  Ian Graham,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[480]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[481]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[482]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[483]  N. Santanello,et al.  Cholesterol reduction yields clinical benefit: impact of statin trials. , 1998, Circulation.

[484]  O. Faergeman,et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[485]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[486]  G. Steinbeck,et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. , 1997, Circulation.

[487]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: animal studies. , 1997, The American journal of clinical nutrition.

[488]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.

[489]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[490]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[491]  N. Santanello,et al.  Cholesterol reduction yields clinical benefit. A new look at old data. , 1995, Circulation.

[492]  M. Seed,et al.  The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. , 1993, Atherosclerosis.

[493]  L. Wilkins.  Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. , 1992, Circulation.

[494]  A. Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[495]  I. Ajzen.  The theory of planned behavior , 1991 .

[496]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[497]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[498]  H. Tyroler,et al.  Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. , 1984, The American journal of cardiology.

[499]  A. Keys.  Serum cholesterol response to dietary cholesterol. , 1984, The American journal of clinical nutrition.

[500]  M. Becker,et al.  Health Belief Model and Personal Health Behavior , 1976 .

[501]  M. Becker.  The Health Belief Model and Sick Role Behavior* , 1974 .

[502]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .